onedb1
01 Aug 2016
I patiently waited this trade had me wondering as the breakout took its time to come but I have never been stopped out So was happy on Friday evening when i checked my positions to see Motif's spike The orders where taken as per outlined plan on my original post Happy DAYS
JudahBenHur
29 Jul 2016
Re: Nasdaq Preliminary prospectus filed Been watching MTFB for a while and got in early this week, looks like I might have just timed this right:[link] BIO FILES PRELIMINARY PROSPECTUS FOR PROPOSED U.S. PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND APPLIES FOR NASDAQ LISTINGMotif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that, further to the notification on 13 July 2016 of the filing of a registration statement with the United States Securities and Exchange Commission (the "SEC"
relating to a proposed public offering of American Depositary Shares ("ADSs" and listing of ADSs on the NASDAQ Global Select Market, the Company has filed an amended registration statement with the SEC, which includes a preliminary prospectus for the proposed offering.SunTrust Robinson Humphrey, Inc. and Ladenburg Thalmann & Co. Inc. are acting as the book-running managers for the offering.
heinro
24 Jun 2016
Drop Obviously going to be a drop after last night's events but this is much more sever than most.Is it because of possible EU funding support now being in danger of withdrawal?SP seems a bit overdone to me!
heinro
05 Jun 2016
Re: Today's Sunday Times coverage Love it " a source close to the company " - so someone who went to th AGM then Lol!Thanks for the AGM notes, all sounds promising.
colebrooke1
05 Jun 2016
Today's Sunday Times coverage [link] float for superbug treatmentsPeter EvansJune 5 2016, 12
1am, The Sunday TimesMotif Bio, which develops antibiotics to fight superbugs, will be valued at close to $100m (£69m) when it floats on the Nasdaq exchange.A London-based antibiotics developer is seeking to exploit a wave of interest in treatments for drug-resistant superbugs by floating on one of America’s biggest stock markets.Motif Bio has appointed US broker MTS Health Partners to handle the offering, which will value the company at close to $100m (£69m) in a float on the Nasdaq exchange later this year. Motif listed on AIM in April last year and will retain a dual listing.A source close to the company said “everything is in place” to launch the float when market conditions pick up in the next six months. The Nasdaq
colebrooke1
05 Jun 2016
Detailed notes from AGM Posted by Timbo003 on ADVFN:Motif’s AGM was held on Thursday June 2nd at Reed and Smith LLP, Broadgate Tower, 20 Primrose Street, London EC2A 2RS. There were approximately 20 attendees of whom around 5 were ordinary shareholders.The Chairman Richard Morgan (RM) opted to commence with the formal business. All the resolutions were passed with large majorities on the proxies with no dissenters at the meeting and no questions regarding any of the resolutions.Graham Lumsden (GL) then gave a 15 minute summary of Motif’s achievements since listing on April 2nd last year, which was more or less a re-worded version of the summary given in the annual report[link] then lead into the Q&A session which lasted for around 30 minutes.Question:With the 10 year exclusivity period granted under QIDP, is it the same start date for both indications (ABSSSI and HABP) or are they staggered?Answer:It is the same start date for both indications, but the oral formulation (should it be successfully developed) should expand the indications and usage of Iclaprim. We hope to file patents concerning the oral formulation which (if granted) would give Motif additional protection for up to 20 years for oral use.Question:One of the reasons frequently given for the dearth of new research and development into new antibiotics is that under the current reimbursement arrangements, it’s just not viable from a commercial perspective. Health authorities would be reluctant to make new novel antibiotics widely available as they would not want common pathogenic bacteria to develop resistance through over-usage, instead they would prefer to keep them in reserve (a treatment of last resort), only to be used in the event of a potential epidemic from bacteria which were resistant to first line antibiotic therapies. This would result in a burst of initial sales (to fill the shelves) but very few repeat sales. What is Motif’s strategy for dealing with this problem?Answer:For Iclaprim, we are only going for indications where the patient is hospitalized, so there is no danger of wide spread use/misuse by GPs or the general population. Furthermore, Iclaprim will not be positioned as an antibiotic of last resort, instead it will be used in place of the current standard of care (SOC). For example, for the skin indication (ABSSSI) the current SOC is Vancomycin.[link] the USA 2.3m patients a year are treated for this condition, 25% of these patients have renal impairment, but Vancomycin is nephrotoxic. One solution is to reduce the dose of Vancomycin for patients with renal impairment but this can lead to a concomitant reduction in efficacy, more risk to the patients, longer stays in hospital and greater readmission rates. Estimated costs (per patient) for hospital based ABSSSI treated with Vancomycin are around $28K. The average length of stay is increased from 13 days for patients with no renal impairment to 19 days for patients with renal impairment. Iclaprim has not shown any signs of nephrotoxicity and therefore could become the SOC for circa 600K patients per annum who are treated for ABSSSI. Two pivotal clinical studies that are currently underway comparing the safety and efficacy of Iclaprim vs Vancomycin, results from this study (if successful) should support this positioning.[link] potential positioning opportunities to consider for Iclaprim (in the future) include:* An alternative for Linezolid which has recently acquired an FDA hypoglycemia warning for diabetics (40% of patients treated with Linezolid are diabetic)[link] An alternative for Daptomycin for patients on statins (where there is
colebrooke1
03 Jun 2016
Pharma Times article mentions Motif Bio Have bought in here think the stock is undervalued and has huge upside potential versus US peers with 5 times the market cap at a similar clinical development stage (hence the upcoming Nasdaq listing).Excerpt below from a recent article in this months Pharma Times about antimicrobial resistance which mentions Motif Bio (great industry coverage):[link] SME using an underutilised mechanism of action is Motif Bio, whose candidate drug was originally developed by Roche. "What is different about iclaprim is that it goes inside the bacteria and inhibits the enzyme dihydrofolate reductase (DHFR)," says CEO Graham Lumsden. "This prevents DNA production by the bacteria, killing them. A lot of antibiotics don't kill the bacteria, they just prevent division, which could leave behind all the genetic material that can mutate and develop resistance."Iclaprim is the only antibiotic with this mechanism, with one exception, he says. "The exception is trimethoprim, however, it is often used in combination with sulphonamides which many patients can't tolerate."Not only is the drug designed to be more potent than trimethoprim – allowing it to be used as monotherapy – it should also tackle the trimethoprim resistance mutation. In tests, bacteria did not develop resistance to the drug after 22 exposures, despite developing resistance to trimethoprim and rifampin after only a couple of exposures, says Lumsden."If you imagine trimethoprim attaching to a bacteria on two sites, if the bacteria mutates and those sites are no longer on the outside there's nothing for trimethoprim to attach to," he says. "Iclaprim uses five, six, seven, eight attachment sites to minimise that risk."
onedb1
01 Jun 2016
Re: Nasdaq Well these things do take time . I have some experience and there is a lot of documentation and I guess PR to get ready . The positive aspect is that comparing value to a peer on the Nasdaq makes the current market cap look small. Am more of a technical trader and this stock was perfect for my strategy and so far am happy Still Long at 47,5p stop loss unchanged at 40p . I may add to this now as my signal was to add today but I was on a long flight so couldn't
pally66
01 Jun 2016
Nasdaq I wonder when we hear news on a possible listing???
onedb1
31 May 2016
Starting to perform 
I like this and suggest those who are out to take a look at chart and various presentations and compare value with equivalent shares in the Nasdaq . Chart wise this is the sort of setup I am pretty much confident with
onedb1
26 May 2016
Re: onedb1 no problems ! I love my job ( trading ) . I like the chart forming here , if I get a chance I will post it for others to discuss
pally66
23 May 2016
onedb1 Thanks for the charts and your interpretations Pally
onedb1
23 May 2016
So far so good and doing what I usually hope these charts should do . Am still Long at 47.5 and no change to stop loss at 40p . Current market seems to be looking positive despite the low volume this share has . I like the rising 20 simple moving average ! I always avoid trading against it . This is trading on the side of the Bulls 50/52 to be regained soon
pally66
19 May 2016
Looing Good I also think the rise today is a lot to do with the press stating the world wide panic over the brake down of current antibiotics and the very urgent need for news ones to combat mrsa and other diseases.Pally
onedb1
19 May 2016
Looking good My entry last week or 2 ago was 47.5 SL 40 as stated . we wobbled but the last 2 days its doing what I'd expect . A formation of a bit of cup may happen . Once we pass 47.5 I suspect 51/52 easy then the next breakout to the up . No change in my view and the position is still live. ( bet many wobbled at 42p lol ) Good thing of a system is that you let the rule do the job for you . Leaving the emotions out of it. If I get stopped its part of the reality and expentancy of my trading system . I don't trade on gut feel or perception . Just 1 day chart as a timeframe and 2 systems TA based / For equities( UK/US) and commodities . 1 is Trend based the other Pattern based ( mostly Ascending/descending Triangles . Easy to set a stop and risk reward assessment
